Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; Departments of Medicine and Physiology, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Cell Metab. 2019 May 7;29(5):1024-1027. doi: 10.1016/j.cmet.2019.04.011.
Diabetic kidney disease (DKD), a major cause of morbidity, mortality, and economic hardship globally, is on the rise. The results of the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have ushered in hope and optimism for the treatment of DKD.
糖尿病肾病（DKD）是全球发病率、死亡率和经济负担的主要原因之一，其发病率正在上升。最近报告的 CREDENCE（卡格列净和已经存在肾病的糖尿病患者中的肾脏事件的临床评估）试验的结果为 DKD 的治疗带来了希望和乐观。
